Direct answer
Melatonin has indication-, timing- and formulation-specific sleep evidence. It is not a universal insomnia treatment; product variability, daytime effects, medication interactions and limited long-term evidence need attention.
Melatonin is a hormone medicine for selected sleep problems; UK prescriptions differ from US supplements. Confidence: high for diagnosis and safety review; limited for universal benefit. No personal regimen is provided. NHS: melatonin overview.
- Timing and alertness matter; sleepiness cannot establish safe driving. NHS: melatonin common questions.
- Slenyto’s pediatric EU licence specifies ages/diagnoses, not routine sleep problems in every child. EMA: Slenyto portal.
- The sampled gummy labels often differed from laboratory contents. That dated test does not certify a current brand. Cohen: 2023 gummy contents study.
- Mouth or throat swelling, breathing or swallowing difficulty can signal serious allergy: seek emergency help immediately. NHS: melatonin adverse effects.
- Discuss persistent sleep problems, other medicines and treatment goals before adding or changing melatonin.
Table of contents
- Evidence summary
- What melatonin is: prescription medicine, supplements and different formulations
- How it works: body-clock timing, immediate release and prolonged release
- Evidence-based care: insomnia, circadian disorders, jet lag and REM behaviour
- Supplement and lifestyle evidence: product quality, routines and commercial claims
- What works and what remains unestablished: scope, conflicts and pediatric uncertainty
- Risks and side effects: daytime impairment, allergy and unintended intake
- Interactions: other sedatives, fluvoxamine, warfarin and altered metabolism
- Who needs specialist assessment: children, pregnancy and breastfeeding
- Clinician-led use: formulation handling, missed doses, review and stopping
- Animal and laboratory evidence: receptor biology is not a treatment outcome
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Adult chronic insomnia | Dated US/European guidance | Connected authors; different scope | CBT-I care context; no independent product ranking. |
| Circadian timing and jet lag | 2015 guideline; CDC chapter; historical review | Trial/author chains not fully closed | Timing-specific assessment, no universal schedule. |
| Children | Current EU licence and 2026 review | Maker label; review trials unclosed | Defined diagnoses/ages; no routine infant indication. |
| Long-term safety | 2023 pediatric review | Public/foundation support; author ties | Puberty/bone evidence unresolved. |
| Product contents | 2023 gummy chemistry study | Connected authors; dated sample | No current brand or lot certification. |
| Breastfeeding | NHS, SPS and Circadin label | Public context versus maker label | Source disagreement; narrow infant scope. |
What melatonin is: prescription medicine, supplements and different formulations
Melatonin is produced in response to darkness and helps time circadian rhythms. US supplements are regulated less strictly than medicines; most supplement melatonin is synthetic. A supplement label or natural claim does not establish medicinal approval or prescription-product equivalence. NCCIH: melatonin education.
Prescription forms include standard and slow-release tablets, capsules and liquid. Specialists sometimes prescribe longer-term for selected children and adults. NHS: melatonin overview.
England’s 2025/26 community prescribing table records 2,992,141 melatonin prescription items. This measures dispensing activity, not individual patients, successful treatment, worldwide demand or US supplement use. NHSBSA: melatonin item count.
Prescription Cost Analysis describes items dispensed in the community in England. Hospital-administered medicines are outside that scope; one person can account for many items. This is a coverage priority signal, not a clinical comparison. NHSBSA: item-count methods.
The annual figures were published on 4 June 2026. They cannot identify why each prescription was issued or establish that every item treated insomnia. NHSBSA: 2025/26 publication.
The practical first step is to identify exactly what is being used: active ingredient, product name, strength, release type and country of supply. Tell the clinician whether it came from a pharmacy, a supplement retailer or an online seller. A familiar hormone name does not make different products interchangeable.
How it works: body-clock timing, immediate release and prolonged release
Melatonin acts through sleep-related brain receptors. Avoid alcohol: combined use can cause excessively deep sleep, breathing problems and difficulty waking. Do not drive or use machinery with sleepiness, dizziness, clumsiness, visual disturbance or poor concentration. NHS: melatonin common questions.
The PiLeJe-funded crossover compared a lower-dose immediate-release sublingual spray with a higher-dose prolonged-release oral tablet in healthy men. Dose, route and release differed together. Its concentration measurements do not establish which form improves insomnia, functioning or long-term safety. PiLeJe: 2023 formulation PK study.
The maker-supplied dissolution experiment examined manipulated tablets in a laboratory. Release measurements do not establish a safe human instruction to crush a particular product. Follow the actual dispensing and product instructions instead. Chua: 2016 dissolution experiment.
A clinician may ask whether the aim is moving a delayed sleep schedule, helping sleep onset or addressing another diagnosed problem. Those are different goals. Taking more, switching delivery route or changing release type can change the question being treated rather than simply strengthen the same treatment.
Evidence-based care: insomnia, circadian disorders, jet lag and REM behaviour
The 2023 European insomnia guideline recommends CBT-I first for chronic adult insomnia. It allows prolonged-release melatonin for a limited period in adults aged 55 or older, while not recommending fast-release melatonin for insomnia without circadian factors. These are attributed recommendations with financial limits, not an independent product ranking. European insomnia guideline: 2023.
The 2015 AASM guideline gives weak recommendations for strategically timed melatonin in specified delayed sleep-wake phase disorder populations. Diagnosis and timing are integral; this is not a universal bedtime regimen. The society funding statement does not clear every supporting trial. AASM: 2015 circadian guideline.
CDC’s 2026 Yellow Book describes jet lag as a mismatch after travel across time zones. Flight direction, light exposure and sleep scheduling affect alignment; wrongly timed melatonin can worsen it. Ask a qualified travel or sleep clinician about the itinerary rather than copying one clock time for every trip. CDC Yellow Book: jet lag.
The 2023 AASM REM sleep behaviour guideline conditionally suggests immediate-release melatonin for selected adults with isolated or secondary RBD. It found insufficient evidence for prolonged release in that role. Protecting the sleeper and bed partner from injury is part of care; ordinary vivid dreams are not a diagnosis of RBD. AASM: 2023 REM behaviour guideline.
Describe symptoms before choosing a sleep product: difficulty sleeping at desired hours, repeated awakenings, loud snoring, breathing pauses, unsafe daytime sleepiness or dream enactment. A sleep diary and a partner’s observations can help the consultation. This guide cannot diagnose the cause or decide which treatment applies.
Supplement and lifestyle evidence: product quality, routines and commercial claims
The US gummy study tested a small set bought in September 2022, usually one sample per brand. Contents often differed substantially from declared melatonin, and one product had no detectable melatonin with CBD present. It measured chemistry, not sleep benefit; it cannot establish the contents of all products, batches or countries today. Cohen: 2023 gummy contents study.
The phytomelatonin review was funded by a seller whose contractors wrote it and whose product it promotes. Its plant-source, antioxidant or mechanistic arguments do not independently establish better clinical efficacy or safety than synthetic melatonin. Minich: 2022 phytomelatonin review.
Keep regular sleep opportunities and discuss practical barriers such as shifts, travel, caregiving, pain and access to CBT-I. A useful review asks what can actually change, not whether somebody followed an idealized routine. Do not assume a routine alone treats an underlying breathing, neurological or mental-health disorder.
Bring photographs or packaging for gummies, sprays and combination products. The pharmacist needs the entire ingredient list, including CBD, herbs and other sedating substances. This article does not endorse a brand, certify a batch or suggest a homemade combination. A quality claim and an outcome claim require different evidence.
What works and what remains unestablished: scope, conflicts and pediatric uncertainty
The 2017 AASM adult chronic-insomnia guideline weakly suggests not using melatonin, based on limited prolonged-release trials in older adults. That differs in date and scope from the European recommendation. It does not prove every formulation ineffective for every circadian disorder, nor does the disagreement independently establish a preferred product. AASM: 2017 insomnia guideline.
The historical Cochrane jet-lag review reported benefit in adult travellers and warned that incorrect timing can delay adaptation. Its public page dates to 2002, with an updating search in 2008 finding no new trials. Full trial funding and supply were not cleared, so its strong wording is not adopted as an independent present-day verdict. Cochrane: historical jet-lag review.
The 2014 publicly supported review found shift-work results inconclusive and did not recommend a melatonin approach. Better sleep measures would not by themselves establish alertness, safe driving or work performance. Its original trials’ financial chains remain unclosed. Costello: 2014 melatonin review.
The January 2026 review found no efficacy evidence for typically developing children aged 0–6 in its included research. Reviewed trials focused on neurological conditions; health or behavioural outcomes beyond two years were not established. Longer prescription records are not controlled proof of long-term safety. Kracht: 2026 young-child review.
The older pooled sleep review combines public and manufacturer-linked fellowship/award funding. It is excluded from the independent efficacy verdict. Pooling different sleep disorders also does not establish one treatment effect for a healthy person seeking general better sleep. Ferracioli-Oda: 2013 sleep review.
Research uncertainty is not proof of no benefit. It means the decision must stay within the population, formulation, duration and outcome actually studied. This guide supplies no independent numerical sleep-gain estimate and no general recommendation to replace established care for another illness with melatonin.
Risks and side effects: daytime impairment, allergy and unintended intake
Effects include tiredness, headache, dizziness, nausea and unusual dreams. Seek urgent clinical help for new confusion, fainting, vision changes or unexplained bleeding. Sudden mouth, tongue or throat swelling, trouble swallowing or breathing, or inability to wake require immediate emergency help: call 999 in the UK or the local emergency number elsewhere. NHS: melatonin adverse effects.
NHS advice is to contact 111 now after taking more than prescribed and feeling unwell; for a child under five it specifies calling rather than using the online service. Do not drive to emergency care. This is not a reason to wait when breathing, consciousness or a serious allergic reaction is affected. NHS: melatonin instructions.
The 2023 pediatric review found nonserious adverse effects and substantial uncertainty about puberty and bone health. Short studies without a demonstrated serious-event increase cannot establish safety for years of use. Its public funder participated in the research, and an author disclosed commercial interests; neither relationship is concealed. Händel: 2023 pediatric safety review.
Keep medicines and supplements where children cannot reach them, preferably in their original container. Record what may have been taken and take the packet to medical care. If an exposure, symptom or amount is uncertain, seek qualified advice rather than estimating from the label or giving another product to counteract it.
Make the review concrete: daytime sleepiness, falls, school or work difficulties, mood changes, nightmares, benefit and adverse effects all matter. A medicine that changes one sleep measure but creates unsafe daytime impairment needs reassessment. Severe reactions take priority over a routine appointment.
Interactions: other sedatives, fluvoxamine, warfarin and altered metabolism
Tell the pharmacist about antidepressants such as fluvoxamine or amitriptyline; benzodiazepines, opioids and Z-drugs; warfarin; oestrogens; some antibiotics and anticonvulsants. These are examples, not a complete list. Do not add sedating herbs or alter prescription doses to compensate for an interaction. NHS: melatonin interactions.
People with epilepsy or blood-thinner treatment need medical supervision when using melatonin supplements. NCCIH: melatonin education.
Circadin’s label describes altered exposure with fluvoxamine and other medicines affecting metabolism, and added impairment with sedatives. It advises avoiding certain combinations and discourages use in pregnancy and breastfeeding. Kidney, liver and autoimmune conditions require product-specific assessment. These licensed precautions are manufacturer-origin information, not an independently established efficacy claim. Circadin: EU product information.
Tell the prescriber about previous melatonin allergy, liver or kidney problems and autoimmune conditions such as lupus, rheumatoid arthritis or multiple sclerosis. The decision depends on the actual product, illness and other medicines; a supplement purchased without a prescription is not exempt from those concerns. NHS: melatonin eligibility.
Include nonprescription pain relief, cough remedies, cannabis, supplements and alcohol in the conversation. Ask the pharmacist to check the entire list before surgery, travel or a new prescription. A list of examples cannot establish that a combination absent from this article is safe.
Who needs specialist assessment: children, pregnancy and breastfeeding
The EU Slenyto licence specifies insomnia in ages 2–18 with autism spectrum disorder and/or neurogenetic disorders involving abnormal daily melatonin secretion and/or nocturnal awakenings, and ages 6–17 with attention-deficit/hyperactivity disorder, when sleep-hygiene measures are insufficient. Healthy infants/all children are not routinely covered. Its product-information posting is newer than the overview. EMA: Slenyto portal.
SPS permits cautious selected melatonin use during breastfeeding for healthy full-term infants, with monitoring for drowsiness, feeding and weight. It reports no published therapeutic breastfeeding evidence. Premature or unwell infants, multiple medicines or concerns require specialist assessment. Avoid bedsharing after sedating medicines. SPS: insomnia during breastfeeding.
NHS says melatonin is usually not recommended in pregnancy because information is limited. Its breastfeeding advice permits assessed use for a healthy infant and warns against bedsharing. This differs from Circadin’s discouraging label; the care team must reconcile the actual product, infant and clinical circumstances. NHS: melatonin reproductive context.
Parents should discuss what is keeping the child awake, behavioural support already tried, daytime functioning and the intended review. Do not copy another child’s prescription, substitute an adult prolonged-release tablet or assume a gummy is the same product. A diagnosis-linked licence does not settle every child’s long-term risk.
Tell the clinician promptly about pregnancy, plans to conceive or infant feeding. This guide provides no fetal-safety guarantee, safe milk threshold, pediatric starting dose or home monitoring schedule. The disagreement between sources calls for individualized assessment, not choosing whichever sentence permits continued use.
Clinician-led use: formulation handling, missed doses, review and stopping
Circadin’s EU licence is for short-term primary insomnia with poor sleep quality in adults aged 55 or older. Its adult course can continue for up to 13 weeks; this is product-specific, not a maximum for all specialist prescribing. The portal updated its product information on 7 July 2025. This is a posting date, not a completed date field in the prescribing text, and does not license every melatonin product for that use. EMA: Circadin portal.
Slenyto tablets must remain whole rather than be broken, crushed or chewed. Its missed-dose instruction depends on whether the child has fallen asleep, unlike generic next-night advice. The label requires periodic benefit/safety review. Follow product-specific dispensing instructions. Slenyto: EU product information.
Food, timing and handling vary between standard and slow-release preparations. The NHS generic missed-dose advice is to skip a forgotten bedtime dose, take the next scheduled dose and never double. Confirm product-specific instructions with the pharmacist. NHS: melatonin instructions.
NHS describes prescribed melatonin as unlikely to cause addiction. Discuss long-term stopping with the clinician; this does not exclude symptoms or review, or permit dose escalation. NHS: melatonin common questions.
Agree on the purpose, how benefit will be assessed and who will review the prescription. Ask what to do after a missed dose or formulation change, when to report adverse effects and how future continuation or stopping will be decided. This article supplies no personal dose, escalation, taper or hormone self-treatment plan.
Animal and laboratory evidence: receptor biology is not a treatment outcome
A receptor mechanism, blood concentration, antioxidant result and clinical sleep benefit are different kinds of evidence. Animal or cell findings cannot establish a human prescription, safe pregnancy exposure, long-term pediatric development or prevention of another illness. Findings about the body’s own hormone do not establish the effects of a marketed supplement.
NCCIH’s May 2024 education describes small, mixed cancer-related studies and advises against delaying conventional treatment. That dated summary does not close the current research landscape or establish melatonin as a cancer treatment. Discuss any proposed complementary use with the treating team. NCCIH: melatonin education.
The commercial formulation experiments described above serve limited chemistry or exposure roles. They do not show that altering a tablet at home is safe, that an earlier concentration peak means better functioning or that a plant source reduces clinical harm. No animal-derived dose or treatment substitution is provided.
Funding and source roles
Research funding at a glance
44 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: melatonin overview | National policy below; page, contributor and study finances unclosed. | England, UK; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review overdue. Public education. |
| NHS: melatonin instructions | National website policy below; page allocation, contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review due has passed. Public-service accuracy incentives; dated advice. |
| NHS: melatonin eligibility | National website policy below; page allocation, contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review due has passed. Public-service accuracy incentives; dated advice. |
| NHS: melatonin adverse effects | National website policy below; page allocation, contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review due has passed. Public-service accuracy incentives; dated advice. |
| NHS: melatonin reproductive context | National website policy below; page allocation, contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review due has passed. Public-service accuracy incentives; dated advice. |
| NHS: melatonin interactions | National website policy below; page allocation, contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review due has passed. Public-service accuracy incentives; dated advice. |
| NHS: melatonin common questions | National website policy below; page allocation, contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; national NHS website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 13 February 2023; February 2026 review due has passed. Public-service accuracy incentives; dated advice. |
| NHS: national website policy | DHSC website funding; no advertising/corporate sponsorship stated. Not individual provider finances or contributor clearance. | England, United Kingdom; national website | Tier 3 — institutional financial/process self-report | B provisional. 14 October 2022; October 2025 review due passed. Accountability and institutional interests; allocation gaps. |
| Circadin: EU product information | Licence holder RAD Neurim Pharmaceuticals EEC SARL, Paris. Commercial product provenance; ultimate owners and exact author payments unclosed. | France holder; EU licence; batch-release sites separately identified | Tier 4 — maker-issued label; self-interest | D for independent outcomes. Approved safety/licensing role; text revision fields are placeholders, not dated revisions. |
| Slenyto: EU product information | Licence holder RAD Neurim Pharmaceuticals EEC SARL, Paris. Commercial product provenance; ultimate owners and exact author payments unclosed. | France holder; EU licence; batch-release sites separately identified | Tier 4 — maker-issued label; self-interest | D for independent outcomes. Approved safety/licensing role; text revision fields are placeholders, not dated revisions. |
| EMA: Circadin portal | Agency fee route below. Applicant/holder documents retain maker provenance; page and assessor allocations unclosed. | Netherlands agency; EU regulatory jurisdiction | Tier 3 — industry-fee regulatory context | C provisional. Product-information posting 7 July 2025; approval does not establish independent efficacy. |
| EMA: Slenyto portal | Agency fees; maker-issued documents; page/assessor allocations unclosed. | Netherlands; EU | Tier 3 — industry-fee regulatory context | C provisional. PI posted 10 June 2026; approval does not clear independent efficacy. |
| EMA: own funding disclosure | Expected 2026 budget mainly pharmaceutical industry fees/charges, with EU and other contributions. Regulatory work compensates national authorities; product-specific allocation unknown. | Netherlands; EU agency | Tier 3 — institutional financial/process self-report | B provisional. 2026 expected budget; not final receipts. Accountability and institutional interests; allocation gaps. |
| EMA: own location | Agency financial route above; identity page does not disclose study or assessor finance. | Netherlands; Domenico Scarlattilaan 6, Amsterdam | Tier 3 — institutional financial/process self-report | B provisional. Current location body read. Accountability and institutional interests; allocation gaps. |
| Neurim: own company account | Own account names founders Nava/Yehuda Zisapel, Circadin/Slenyto commercialization and partner licensing. Ultimate beneficial ownership/full receipts unclosed. | Israel; own contact HaBarzel 27, Tel Aviv; French licence holder distinct | Tier 4 — seller self-report; self-interest | D. Commercial promotion; unrelated promotional copy on the page adds an integrity caveat. Regulatory holder independently cross-checked. |
| AASM: 2015 circadian guideline | AASM funded; original says no industry support and no author financial conflicts. Current society route below; included-trial procurement/finance unclosed. | United States; AASM, Darien, Illinois | Tier 2 — guideline context; provisional | C provisional. Weak recommendations; dated declarations and incomplete trial chain. |
| AASM: 2017 insomnia guideline | Neubauer: Purdue consulting; Krystal: Merck/TEVA/Sunovion relationships; Buysse: commercial consulting/IP; Heald: AASM staff. Current reviewer contracts and original-trial finance unclosed. | United States; AASM, Darien, Illinois; NIH hosting not funding | Tier 3 — connected authors; care context | C. Transparent dated declarations; weak melatonin recommendation, no independently cleared outcome. |
| AASM: 2023 REM behaviour guideline | AASM funded; Howell reports commercial sleep-education co-ownership/consulting, with other society roles disclosed. Reviewer contracts and included trials unclosed. | United States; AASM, Darien, Illinois | Tier 3 — connected author/society context | C provisional. Conditional recommendation; immediate-release scope, not generic insomnia efficacy. |
| AASM: own 2023 financial disclosure | Industry cash/in-kind exhibits, sponsorship, advertising and engagement income disclosed, including drug makers. Guideline allocations and current receipts unclosed. | United States; 2510 North Frontage Road, Darien, Illinois | Tier 3 — institutional financial/process self-report | B provisional. Calendar 2023; page 30 July 2024, not current audited accounts. Accountability and institutional interests; allocation gaps. |
| European insomnia guideline: 2023 | ESRS paid English proofreading; authors state no other financial support. Later lead-author ties below; full original author appendix unavailable. | European guideline; lead Freiburg, Germany | Tier 3 — connected lead provenance; care context | C provisional. Dated guidance; original COI supplement 403. Current/historic receipts not inferred. |
| Riemann: 2026 declared interests | 9 April 2026 original: lead Riemann discloses Idorsia/Heel speaking and consultancy, plus digital-therapy firms. Not proof of 2023 or page payment. | Germany; corresponding author Freiburg | Tier 3 — commercial author interests | C for connected-source provenance. Actual declaration/affiliations read; subscription clinical body not used. |
| NCCIH FY 2025 congressional justification | NIH/HHS federal budget route; historical request, not current enactment. Gifts/page allocation unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional historical self-report. Page says it no longer reflects current HHS policy; budget-advocacy incentives. |
| SPS: own commissioning disclosure | NHS England commissioning of provider-trust contracts/subcontracts. Stated contracts end 31 March 2026; subsequent renewal and page allocation unverified. | England, UK; multiprovider network | Tier 3 — institutional funding/process self-report | B provisional dated disclosure. Current October 2026 arrangements and contributors’ interests unknown. |
| NHSBSA: 2025/26 audited institutional accounts | DHSC sponsor/appointed board; main Parliamentary support plus full-cost service-contract income and public repayment work. Separate student-support routes. Specific PCA allocation and staff/contractor interests unknown. | United Kingdom; Stella House, Goldcrest Way, Newcastle upon Tyne | Tier 3 — institutional financial/identity self-report | B provisional. Report printed 13 July 2026. Accountability/service incentives; selected notes read, complete subsidiary/backer audit unclosed. |
| Cochrane: historical jet-lag review | Publisher accounts below. Public abstract does not close review grants, author contracts or individual trial funding/product supply. | United Kingdom publisher; London; travellers across countries | Tier 2 — historical review context; provisional | C provisional. Published 22 April 2002; 2008 search found no new trials. Not a current independent product verdict. |
| Cochrane: 2024 trustees/accounts | Charity/company; Wiley publishing royalties, software/learning/service fees, grants, events and interest. No 2002 review allocation inferred. | United Kingdom; registered England/Wales, London | Tier 3 — institutional financial/process self-report | B provisional. Year ended 31 December 2024. Accountability and institutional interests; allocation gaps. |
| CDC Yellow Book: jet lag | CDC routes and book declarations below. Riedy/Williams not named in disclosed commercial list; editors’ ties and original trials remain separate. | United States; authors WRAIR/USU, Maryland; CDC Atlanta | Tier 2 — public travel context; provisional | C provisional. Author no-conflict self-statement does not clear signed forms, allocations or trials. |
| CDC Yellow Book: author declarations | Remaining authors report no content conflict; Riedy/Williams omitted from commercial list. Other editors/authors disclose industry relationships. Full signed forms unavailable. | United States; CDC Atlanta; named military authors Maryland | Tier 3 — institutional financial/process self-report | B provisional. 2026 edition. Accountability and institutional interests; allocation gaps. |
| CDC: FY2026 operating plan | Federal appropriations and statutory fund routes. Exact chapter allocation and current private receipts unclosed; gift authority separate below. | United States; federal CDC | Tier 3 — institutional financial/process self-report | B provisional. FY2026 final operating plan. Accountability and institutional interests; allocation gaps. |
| CDC: dated gift policy | Direct gifts and CDC Foundation transfers permitted with conflict review. Authority does not establish any actual gift or chapter sponsor. | United States; federal CDC | Tier 3 — institutional financial/process self-report | B provisional. Updated 21 December 2016; reviewed 5 October 2022. Accountability and institutional interests; allocation gaps. |
| CDC: own contact identity | Institutional route above; address is not disease-page or military-author financial clearance. | United States; 1600 Clifton Road NE, Atlanta, Georgia | Tier 3 — institutional financial/process self-report | B provisional. Own agency address previously read. Accountability and institutional interests; allocation gaps. |
| Kracht: 2026 young-child review | NIH grants to Kracht/Wallisch; no author conflicts reported. Underlying-trial finance/supply and full supplement were not closed. | United States; lead Kansas City, Kansas | Tier 2 — publicly funded review; provisional | B provisional. Transparent funding; sparse heterogeneous studies, no independent product efficacy adopted. |
| Händel: 2023 pediatric safety review | Danish Health Authority funded/participated; Parker Institute Oak Foundation support. Virring: past AGB Pharma/Takeda/Medice lectures and Novo Nordisk shares. Trials unclosed. | Denmark authors; SDU mirror is host, not review funder | Tier 3 — commercially connected author context | C. Public/foundation review funding distinguished from author interests; long-term evidence very uncertain. |
| Cohen: 2023 gummy contents study | Cohen reports nonprofit grants, royalties/litigation; Khan public grants and supplement-industry conference support. No maker trial funding inferred. | United States; Massachusetts/Mississippi researchers | Tier 3 — connected researcher context | C provisional. Single-time product testing; chemistry, not sleep efficacy or every current lot. |
| PiLeJe: 2023 formulation PK study | PiLeJe funded; five employee authors and Claustrat company consulting disclosed. Product-selling interests direct; ultimate owners unclosed. | France; PiLeJe Paris and French study sites | Tier 4 — manufacturer-funded study; self-interest | D for outcomes. Open crossover pharmacokinetics; dose, route and release confounded, no sleep outcome. |
| Chua: 2016 dissolution experiment | Flynn supplied products/materials; King’s Health Partners academic support. Declared no conflicts does not remove maker-supply provenance. | United Kingdom; King’s College London/Flynn Stevenage | Tier 4 — manufacturer-supplied experiment | D for independent outcomes. Laboratory release testing, not human permission to crush or clinical benefit. |
| Minich: 2022 phytomelatonin review | Symphony Natural Health funded; all authors contractors; company sells Herbatonin. Ultimate owners/current receipts unclosed. | United States; seller West Valley City, Utah | Tier 4 — seller-funded review; self-interest | D. Direct plant-product promotion; no independent natural-versus-synthetic safety superiority. |
| Ferracioli-Oda: 2013 sleep review | Mixed public/academic support includes APIRE/Eli Lilly fellowship and AACAP/Eli Lilly award. No-role declaration does not remove sponsorship. | United States/Brazil author institutions | Tier 4 — mixed manufacturer funding; self-interest | D for independent outcomes. Heterogeneous pooled disorders; no universal sleep estimate adopted. |
| Costello: 2014 melatonin review | Defense Health Program/USUHS human-performance support; authors report no financial conflicts. Included-trial finance/product characterization unclosed. | United States; military/academic author institutions | Tier 2 — publicly funded review; provisional | C provisional. Inconclusive shift-work findings; dated and incompletely traced supporting trials. |
| NCCIH: melatonin education | Dated fiscal route below. Credited reviewers Hopp/Shurtleff; their outside interests, page allocation and supporting studies unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. May 2024; some supporting research older. Public education, not conflict-cleared product efficacy. |
| SPS: insomnia during breastfeeding | SPS-specific commissioning below. Page contributors’ outside interests and supporting-study finance unclosed. | England, United Kingdom; multiprovider pharmacy service | Tier 2 — specialist clinical context; provisional | C provisional. 8 March 2024; no published therapeutic breastfeeding evidence, narrow infant scope. |
| NHSBSA: melatonin item count | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: item-count methods | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 3 — institutional method self-report | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: 2025/26 publication | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
Frequently asked questions
Is melatonin a supplement or a prescription medicine? It depends on the country and product. UK prescribing and US supplement sales have different regulatory contexts. NHS: melatonin overview.
Does melatonin replace CBT-I for chronic insomnia? No. The adult guideline recommends CBT-I first; its melatonin advice is age- and formulation-specific. European insomnia guideline: 2023.
Can I crush a prolonged-release tablet for my child? Do not crush Slenyto. Confirm the exact product and a suitable formulation with the pharmacist. Slenyto: EU product information.
Is years of melatonin use proven safe for a healthy young child? No. Evidence for typically developing young children and long-term developmental outcomes remains limited. Kracht: 2026 young-child review.
Is melatonin automatically safe during breastfeeding? No. The specialist advice has narrow infant eligibility, limited evidence and an individual assessment requirement. SPS: insomnia during breastfeeding.
What if melatonin causes throat swelling or difficulty breathing? Seek emergency help immediately. Call 999 in the UK or the local emergency number elsewhere. NHS: melatonin adverse effects.
Sources and funding notes
Reviewed 4 October 2026. UK medicine advice, EU product licensing and US supplement sales are distinguished. NHS clinical pages retain February 2023 review dates; review deadlines have passed. Portal posting dates do not fill blank prescribing-text revision fields. Company and licence-holder countries differ from batch-release sites; Circadin identifies Germany, Portugal and Spain, while Slenyto identifies Portugal. Ultimate ownership and current receipts remain unclosed. The 2023 guideline’s funding is separate from the later lead-author declaration. Public review funding does not financially clear every underlying trial. Manufacturer/seller-funded, supplied or issued sources are Tier 4/D for independent outcomes. Chemistry, pharmacokinetics, licensed care and efficacy have separate roles. Source concentration is primarily UK/US/EU; worldwide licensing and individual patient suitability are not closed. No personal regimen or independent numerical benefit estimate is supplied.
- NHS: melatonin overview — Prescription forms and UK clinical-use context.
- NHS: melatonin instructions — Formulation-specific handling and extra-intake care.
- NHS: melatonin eligibility — Conditions requiring prescriber assessment.
- NHS: melatonin adverse effects — Sedation, serious reactions and immediate allergy care.
- NHS: melatonin reproductive context — Pregnancy uncertainty and assessed breastfeeding use.
- NHS: melatonin interactions — Selected interactions; no personal adjustment.
- NHS: melatonin common questions — Mechanism, impairment, alcohol and stopping context.
- NHS: national website policy — National process disclosure only.
- Circadin: EU product information — Circadin-specific indication, precautions and formulation handling.
- Slenyto: EU product information — Slenyto-specific indication, precautions and formulation handling.
- EMA: Circadin portal — Portal date and product-specific licensing context.
- EMA: Slenyto portal — Posting date and licence scope.
- EMA: own funding disclosure — Institutional route, not capture or outcome proof.
- EMA: own location — Agency headquarters, distinct from product manufacture.
- Neurim: own company account — Corporate stakes only; no product benefit adopted.
- AASM: 2015 circadian guideline — Strategically timed melatonin for specified circadian disorders.
- AASM: 2017 insomnia guideline — Adult chronic-insomnia recommendation and scope.
- AASM: 2023 REM behaviour guideline — Selected adult REM sleep behaviour disorder care.
- AASM: own 2023 financial disclosure — Institutional route, not sponsorship of every guideline.
- European insomnia guideline: 2023 — CBT-I first; formulation/age-specific prescribing context.
- Riemann: 2026 declared interests — Dated author relationship only.
- NCCIH FY 2025 congressional justification — Institutional route only; no present appropriation or product efficacy.
- SPS: own commissioning disclosure — SPS-specific route; national NHS website policy not substituted.
- NHSBSA: 2025/26 audited institutional accounts — Institutional finance only; no drug efficacy, item accuracy or maker influence inferred.
- Cochrane: historical jet-lag review — Historical travel findings and timing caution.
- Cochrane: 2024 trustees/accounts — Publisher revenue, separate from author/trial funding.
- CDC Yellow Book: jet lag — Flight, light and melatonin timing; no self-treatment timetable.
- CDC Yellow Book: author declarations — Source-specific author/process limits, not blanket book clearance.
- CDC: FY2026 operating plan — Institutional enacted operating context, not trial finance.
- CDC: dated gift policy — Gift permission only; no donor payment inferred.
- CDC: own contact identity — Agency location distinct from chapter authors’ institutions.
- Kracht: 2026 young-child review — Young-child evidence and long-term outcome gaps.
- Händel: 2023 pediatric safety review — Nonserious effects and unresolved puberty/bone safety.
- Cohen: 2023 gummy contents study — Label-content discrepancy in sampled US gummies.
- PiLeJe: 2023 formulation PK study — Formulation comparison limits; no superiority claim.
- Chua: 2016 dissolution experiment — Release-profile mechanism only.
- Minich: 2022 phytomelatonin review — Commercial research context only.
- Ferracioli-Oda: 2013 sleep review — Why public grants do not independently clear a review.
- Costello: 2014 melatonin review — Shift-work uncertainty; sleep differs from work safety.
- NCCIH: melatonin education — Supplement regulation and uncertainty, not an efficacy ranking.
- SPS: insomnia during breastfeeding — Cautious individual feeding assessment, not blanket safety.
- NHSBSA: melatonin item count — England community prescription items, not patients or benefit.
- NHSBSA: item-count methods — Community versus hospital scope and item definition.
- NHSBSA: 2025/26 publication — Date and scope, not worldwide popularity.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
